Compare
Airsculpt Technologies, Inc. vs LifeMD, Inc. vs Cardiff Lexington Corp
| Latest fiscal year | Airsculpt Technologies, Inc. AIRS | LifeMD, Inc. LFMD | Cardiff Lexington Corp CDIX |
|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $151.82M | $194.06M | $11.54M |
| Revenue growth (YoY) | -15.8% | +25.3% | +39.5% |
| Gross margin | n/a | 85.7% | 62.5% |
| Operating margin | -7.6% | -4.0% | 9.5% |
| Net margin | -7.7% | 7.4% | -47.7% |
| Net income | -$11.67M | $14.35M | -$5.51M |
| EPS (Diluted) | -$0.19 | $0.25 | n/a |
| Operating cash flow | $3.10M | $8.28M | -$2.85M |
| Free cash flow | $692.0K | $6.41M | n/a |
| Cash & equivalents | $8.45M | n/a | n/a |
| Total assets | $187.30M | $70.41M | $29.09M |
| Total liabilities | $99.59M | $47.25M | $26.01M |
| Shareholders' equity | $87.71M | $23.16M | -$2.47M |
| Return on year-end equity | -13.3% | 62.0% | n/a |
| Shares outstanding | 64.46M | 46.66M | 13.70M |
Revenue, most recent five fiscal years
| Fiscal year | Airsculpt Technologies, Inc. | LifeMD, Inc. | Cardiff Lexington Corp |
|---|---|---|---|
| Latest | $151.82M Ended 2025-12-31 | $194.06M Ended 2025-12-31 | $11.54M Ended 2025-12-31 |
| 1 year earlier | $180.35M Ended 2024-12-31 | $154.82M Ended 2024-12-31 | $8.27M Ended 2024-12-31 |
| 2 years earlier | $195.92M Ended 2023-12-31 | $152.55M Ended 2023-12-31 | $11.85M Ended 2023-12-31 |
| 3 years earlier | $168.79M Ended 2022-12-31 | $119.03M Ended 2022-12-31 | $10.69M Ended 2022-12-31 |
| 4 years earlier | $133.31M Ended 2021-12-31 | $92.88M Ended 2021-12-31 | $9.88M Ended 2021-12-31 |